Therefore, this new technology has potential to target multiple tumor types, as PDL1-scFv is not tumor specific, and coat the tumor cell with an antigen that will recruit preexisting antigen-specific CD8+ T cells to target the tumor. The gene discussed is CD8A; the disease is neoplasm.